logo-loader
viewe-Therapeutics plc

e-Therapeutics positioned to progress drugs in clinical pipeline, says Edison

drug_research_350_5267f8d33ed93.jpg

e-Therapeutics (LON:ETX), with £45mln in cash, is well funded and has the resources to progress its two drugs in clinical development through to potential "value inflection points".

So says research house Edison, which says there is potential upside in the shares from factors, including clinical progress and future collaborations.

In the ETS2101 clinical programme for Dexanabinol, results from the US are expected in the fourth quarter (for brain cancer) and the first quarter next year from the UK (for solid tumours).

Phase II trials for ETS2101 and for ETS6103, for depression, are in planning, with the latter due to start imminently, says Edison analyst Franc Gregori.

He says the firm's current enterprise value of £34mln is supported by its existing pipeline, without value attributed from its technology platform or intellectual property.

The firm's shares are currently chnaging hands at 30p each.


Quick facts: e-Therapeutics plc

Price: 3.25 GBX

AIM:ETX
Market: AIM
Market Cap: £8.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

4 weeks ago

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read